Abstract
The pharmacokinetic study of drugs, analysis of the time course of a drug substance in the body, is no longer novel in clinical therapeutics. The application of the concepts of pharmacokinetics to the discovery and development of better therapeutic agents, particularly within the pharmaceutical industry, is growing rapidly. There are several aspects of this process which are particularly important in the development of antimicrobial agents. Thus, for example, drug discovery projects are now focussing on the need to achieve high systemic availability following oral administration; the potential benefit in targeting drugs to particular tissues such as the CNS or via specific routes of elimination such as in urine or body secretions to treat topical infections; and the need to obtain drugs with a sufficiently long duration of action to achieve once daily dosing. In addition, the relationship between the in vitro potency of drugs in primary screens and their efficacy in vivo is often poorly understood, and discovery project scientists often cannot rationalise the efficacy of their novel compounds in vivo without an awareness of their pharmacokinetics. Consequently, both the practising clinician and the project scientist need to have an understanding of what impact the pharmacokinetic profile of the drugs they propose for antifungal therapy will have on their efficacy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Atkinson AJ, Bennett JE (1978) Amphotericin B pharmacokinetics in humans. Anti-200 microb Agents Chemother 13: 271–276
Baxter JG, Brass C, Schentag JJ, Slaughter RL (1986) Pharmacokinetics of keto- conazole administered intravenously to dogs and orally as tablets and solution to humans and dogs. J Pharm Sci 75: 443–447
Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Ailing DW (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatmentj)f cryptococcal meningitis. N Engl J Med 301: 126–131
Bindschadler DD, Bennett JE (1969) A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 120: 427–436
Block ER, Bennett JE, Livoti LG, Klein WJ, MacGregor RR, Henderson L (1974) Flucytosine and amphotericin B: haemodialysis effects on the plasma concentration and clearance. Ann Int Med 80: 613–617
Boelaert J, Daneeis R, Van Lunduyt H, Symoens J (1976) Miconazole plasma levels in healthy subjects and in patients with impaired renal function. In: Williams JD, Geddes AM (eds) Chemotherapy, Proc 9th Int Cong Chemother, London, vol 6. Plenum, New York, pp 165–169
Borelli D, Bran JL, Fuentes J, Legendre R, Leiderman E, Levine HB, Restrepo MA, Stevens DA (1979) Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J 55: 657–661
Brammer KW, Tarbit MH (1987) A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 141–149
Brass C, Galgiani JN, Blaschke TF, Defelice R, O’Reilly RA, Stevens DA (1982) Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother 21: 151–158
Brugmans J, Van Cutsem J, Heykants J, Schuermans V, Thienpont D (1972) Systemic antifungal potential, safety, biotransport and transformation of miconazole nitrate. Eur J Clin Pharmacol 5: 93–99
Büchel KH, Draber W, Regel E, Plempel M (1972) Synthesen und Eigenschaften von Clotrimazol und weiteren antimykotischen 1-Triphenylmethylimidazolen. Arzneimittelforsch 22: 1260–1272
Cauwenbergh G, De Doncker P (1987) The clinical use of itraconazole in superficial and deep mycoses. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 273–284
Craven PC, Ludden TM, Drutz DJ, Rogers W, Haegele KA, Skrdlant HB (1979) Excretion pathways of amphotericin B. J Infect Dis 140: 329–341
Craven PC, Graybill JR, Jorgensen JH, Dismukes WE, Levine BE (1983) High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Int Med 98: 160–167
Daneshmend TK, Warnock DW (1983) Clinical pharmacokinetics of systemic anti-fungal drugs. Clin Pharmacokinet 8: 17–42
Daneshmend TK, Warnock DW (1988) Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 14: 13–34
Daneshmend TK, Warnock DW, Turner A, Roberts CJC (1981) Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother 8: 299–304
Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ (1984) Influence of food on the pharmacokinetics of keto-conazole., Antimicrob Agents Chemother 25: 1–3
Dawborn JK, Page MD, Schiavone DJ (1973) Use of 5-fluorocytosine in patients with impaired renal function. Br Med J 4: 382–384
Duhm B, Maul W, Medenwald H, Patzschke K, Puetter J, Wegner LA (1974) The pharmacokinetics of clotrimazole 14C. Postgrad Med J (July Suppl): 13–16
Gascoigne EW, Barton GJ, Michaels M, Meuldermans W, Heykants J (1981) The 201 kinetics of ketoconazole in animals and man. Clin Res Rev 1: 177–187
George CF, Shand DG (1982) Presystemic drug metabolism in the liver. In: George CF, Shand DG, Renwick AG (eds) Clinical pharmacology and therapeutics. 1. Presystemic drug elimination. Butterworth, London, pp 69–77
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
Graybill JR, Craven PC (1983) Antifungal agents used in systemic mycoses: activity and therapeutic use. Drugs 25: 41–62
Heel RC, Brogden RN, Speight TM, Avery GS (1978) Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 16: 177–201
Heel RC, Brogden RN, Pakes GN, Speight TM, Avery GS (1980) Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 19: 7–30
Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS (1982) Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23: 1–36
Henderson JT (1987) Fluconazole - a significant advance in the management of human fungal disease. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 77–79
Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron JC, Woestenborghs R, Cauwenbergh G (1987) The pharmacokinetics of itraconazole in animals and man: an overview. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 223–249
Hostetier KA, Wrighton SA, Molowa DT, Thomas PE, Levin W, Guzelian PS (1989) Conduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Mol Pharmacol 35: 279–285
Huang Y-C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J (1986) Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Anti- microb Agents Chemother 30: 206–210
Humphrey MJ, Jevons S, Tarbit MH (1985) Pharmacokinetic evaluation of UK- 49,858, a metabolically stable triazole antigungal drug, in animals and humans. Antimicrob Agents Chemother 28: 648–653
Jevons S, Gymer GE, Brammer KW, Cox DA, Leeming MRG (1979) Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother 15: 597–602
Lewi PJ, Boelaert J, Daneels R, De Meyere R, Van Landuyt H, Heykants JJP, Symoens J, Wynants J (1976) Pharmacokinetic profile of intravenous miconazole in man: comparison of normal subjects and patients with renal insufficiency. Eur J Clin Pharmacol 10: 49–54
Marriott MS, Richardson K (1987) The discovery and mode of action of fluconazole. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 81–92
Marriott MS, Baird JRC, Brammer KW, Faccini J, Faulkner JK, Halliwell G, Jevons S, Monro AM, Nachbaur J, Perraud J, Tarbit MH (1983) Tioconazole, a new broad-spectrum antifungal agent: preclinical studies related to vaginal candidiasis. Gynak Rdsch 23 [Suppl 1]: 1 — 11
Menz HP, Teltscher U, Bayer C, Oldershausen HF (1973) Zur Pharmakokinetik des oralen Antimykotikums Clotrimazole beim Menschen. Dtsch Med Wochenschr 98: 1606–1609
Midgley I, Biggs SR, Hawkins DR, Chasseaud LF, Darragh A, Brodie RR, Walmsley LM (1981) The metabolic fate of [3H]econazole in man. Xenobiotica 11: 595–608
Nakano M, Nakajima Y, Iwatani K, Ikenishi Y, Nakagawa Y, Sugeno K (1989) Metabolism of the antimycotic agent, croconazole, in rabbits. Drug Metab Dispos 17: 323–329
Odds FC (1980) Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother 6: 749–761
Odds FC (1986) A survey of old and new antifungal tests in vitro. In: Iwata K, Vanden Bossche H (eds) In vitro and in vivo evaluation of antifungal agents. Elsevier, Amsterdam, pp 13–19
Pennington JE, Block ER, Reynolds HY (1974) 5-Fluorocytosine and amphotericin B 202 in bronchial secretions. Antimicrob Agents Chemother 6: 324–326
Polak A (1979) Pharmacokinetics of amphotericin B and flucytosine. Postgrad Med J 55: 667–670
Polak A, Dixon DM (1987) In vitro/in vivo correlation of antifungal susceptibility testing using 5-fluorocytosine and ketoconazole as examples of two extremes. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 45–59
Remmel RP, Amoh K, Abdel-Monem lM (1987) The disposition and pharmacokinetics of ketoconazole in the rat. Drug Metab Dispos 15: 735–739
Richardson K, Brammer KW, Marriott MS, Troke PF (1985) Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 27: 832–835
Richardson K, Andrews RJ, Marriott MS, Tarbit MH, Troke PF (1986) Correlation of in vitro and in vivo activity of azole antifungals. In: Iwata K, Vanden Bossche H (eds) In vitro and in vivo evaluation of antifungal agents. Elsevier, Amsterdam, pp 147–149
Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ (1988) Design and evaluation of a systemically active agent, fluconazole. Ann NY Acad Sci 544: 4–11
Ritter W (1985) Pharmacokinetic fundamentals of vaginal treatment with clotrim-azole. Am J Obstet Gynecol 152: 945–947
Ritter JK, Franklin MR (1987) Induction and inhibition of rat hepatic drug metabolism by N-substituted imidazole drugs. Drug Metab Dispos 15: 335–343
Ritter W, Patzschke K, Krause U, Stettendorf S (1982) Pharmacokinetic fundamentals of vaginal treatment with clotrimazole. Chemotherapy 28 [Suppl]: 37–42
Rodrigues AD, Wadell PR, Ah-Sing E, Morris BA, Wolf CR, Ioannides C (1988) Induction of the rat hepatic microsomal mixed-function oxidases by 3 imidazole- containing antifungal agents: selectivity for the cytochrome P-450IIB and P-450III families of cytochromes P-450. Toxicology 50: 283–301
Rolinson GN (1980) The significance of protein binding of antibiotics in antibacterial chemotherapy. J Antimicrob Chemother 6: 311–317
Rowland M, Tozer TN (1988) Clinical pharmacokinetics: concepts and applications. Lea and Febiger, Philadelphia
Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS (1975) Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs 9: 424–447
Schönebeck J, Polak A, Fernex M, Scholer HJ (1973) Pharmacokinetic studies on the oral antimycotic agent 5-flurocytosine in individuals with normal and impaired kidney function. Chemotherapy 18: 321–336
Seo, M, Iida H, Miura Y (1977) Basic experiments with clotrimazole administered orally. Curr Med Res Opinion 5: 169–178
Stevens DA, Levine HB, Deresinski SC (1976) Miconazole in coccidioidomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med 60: 191–202
Symoens J, Cauwenbergh G (1983) Ketoconzole, a new step in the management of fungal disease. Prog Drug Res 27: 63–84
Thienpont D, Van Cutsem J, Van Nueten JM, Niemegeers CJE, Marsboom R (1975) Biological and toxicological properties of econazole, a broad-spetrum antimycotic. Arzneimittelforsch 25: 224–230
Troke PF (1987) Efficacy of fluconazole in animal models of superficial and opportunistic systemic fungal infection. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 103–112
Troke PF, Marriott MS, Richardson K, Tarbit MH (1988) In vitro potency and in vivo activity of azoles. Ann NY Acad Sei 544: 284–293
Van Cutsem JM, Thienpont D (1972) Miconazole, a broad-spectrum antimycotic 203 agent with antibacterial activity. Chemotherapy 17: 392–404
Van Cutsem J, Van Gerven F, Janssen PAJ (1987a) Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 9: S15–S32
Van Cutsem J, Van Gerven F, Janssen PAJ (1987b) The in vitro and in vivo antifungal activity of itraconazole. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 177– 192
Van Der Meer JWM, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J (1980) The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother 6: 552–554
Wade DN, Sudlow G (1972) The kinetics of 5-fluorocytosine elimination in man. Aust NZ J Med 2: 153–158
Wilkinson GR, Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Wise R (1986) The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 11: 470–482
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Tarbit, M.H. (1990). Pharmacokinetic Aspects of Antifungal Therapy. In: Ryley, J.F. (eds) Chemotherapy of Fungal Diseases. Handbook of Experimental Pharmacology, vol 96. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75458-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-75458-6_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75460-9
Online ISBN: 978-3-642-75458-6
eBook Packages: Springer Book Archive